FDA Orange Book · active-ingredient family
Lasmiditan succinate
Lasmiditan succinate is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:REYVOW · NDA 211280
1
Brand (NDA)
0
Generics (ANDA)
4
Listed patents
0
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| REYVOWRLD×3 | ELI LILLY AND CO | NDA 211280 | — | Jan 31, 2020 |
Listed patents (4)
| Patent | Expires | In | Type |
|---|---|---|---|
| 7423050 | Feb 17, 2028 | in 1 yr 8 mo | SubstanceProductU-1719 |
| 12257246 | Jul 07, 2030 | in 4 yr 1 mo | U-2718 |
| 11053214 | Dec 05, 2037 | in 11 yr 8 mo | SubstanceProductU-1719 |
| 12071423 | Jul 06, 2040 | in 14 yr 3 mo | Product |
Lasmiditan succinate — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
